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Abstract
Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes as well as patient factors that impact
the capacity to deliver treatment. How the relative importance of these factors changes with patient age has not previously been
investigated comprehensively. We analyzed data from 3894 patients of all ages uniformly treated in a large clinical trial of
myeloma patients, Myeloma XI. Even with novel therapeutic approaches progression-free survival (PFS) and overall survival
(OS) are affected by age with a stepwise reduction in PFS and OS with each decade increase. Renal function deteriorated with
increasing age whilst the frequency of t(4;14) and del(17p) decreased and gain(1q) increased. The relative contribution of
performance status, international staging score and molecular risk to progression-free and overall survival varied by age group.
Molecular events have a larger effect on outcome in younger patients with their relative contribution diminishing in the elderly.
Performance status is important for patient outcome at all ages suggesting that physical frailty may be a more important
predictor of outcome than age itself. Signiﬁcant differences in the factors driving patient outcomes at different ages are
important to consider as we design disease segmentation strategies to deliver personalized treatment approaches.
Background
Myeloma patient outcomes have improved in the last two
decades following the introduction of proteasome inhibitor
and immunomodulatory drug therapies. However, there
remains a subset of patients with high-risk disease who
continue to have poor outcomes [1, 2]. Phenotypically,
high-risk myeloma is characterized by early progression and
death. Factors contributing to poor outcomes include
patient-related variables, such as comorbidities and organ
reserve limiting treatment delivery [3], and tumor-related
factors such as enhanced proliferation and apoptosis resis-
tance driven by molecular driver lesions [1].
From a molecular point of view there is not one single
lesion universally associated with high-risk disease but
rather this is due to the interplay of a range of different
molecular abnormalities. Chromosomal abnormalities
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typical of myeloma include the tumor initiating lesions
hyperdiploidy and translocations involving the immu-
noglobulin regions and lesions associated with disease
progression, such as copy number change [4–6]. Translo-
cations t(4;14), t(14;16) and t(14;20) together with the copy
number abnormalities del(17p), gain/amp(1q) have all been
associated with adverse outcomes and the presence of more
than one adverse lesion is associated with even worse
prognosis [7–9]. Mutations have also been associated with
poor outcomes with biallelic inactivation of TP53 by
mutation and/or deletion associated with the worst out-
comes [10–12].
Most molecular studies to date have been conducted with a
focus on younger patients. In older patients it has become
increasingly apparent that outcomes are nuanced by physical
functioning and comorbidities, which play a role in treatment
tolerability and the dose intensity delivered over time. This
suggests that not all factors predictive of outcome will have
equal signiﬁcance at all ages. Unfortunately, recruitment of
older patients to clinical trials is often difﬁcult and few trials
have sufﬁcient power to examine the true impact of different
variables in patients over the age of 75 years [13, 14].
In this work we determined the relative contribution of
patient and disease factors on clinical outcome and how
these are impacted by age in a uniformly treated trial
population in the UK NCRI Myeloma XI study.
Methods
Myeloma XI is a multicenter, phase III, open-label, rando-
mized controlled trial for newly diagnosed myeloma
patients, with pathways for transplant eligible and non-
eligible patients. The trial recruited 3894 patients from both
academic and district general hospitals around the UK
between 2010 and 2016. The study was approved by the
national ethics review board (National Research Ethics
Service, London, UK), institutional review boards of the
participating centers, and the competent regulatory authority
(Medicines and Healthcare Products Regulatory Agency,
London, UK), and was undertaken according to the
Declaration of Helsinki and the principles of Good Clinical
Practice as espoused in the Medicines for Human Use
(Clinical Trials) Regulations. Informed consent was
obtained from all patients. Some of the primary study out-
comes have been reported elsewhere [15]. The study was
designed to be representative of the general myeloma
population in the UK with only a few exclusion criteria.
Eligible patients for the overall study were aged ≥18 years
and had newly diagnosed MM, based on paraprotein in
serum and/or urine, bone marrow clonal plasma cells or
plasmacytoma, and myeloma-related symptoms or organ or
tissue impairment. Patients were excluded if they had other
previous or concurrent malignancies, including myelodys-
plastic syndromes; prior treatment for myeloma (excluding
local radiotherapy, bisphosphonates, and corticosteroids);
grade ≥ 2 peripheral neuropathy; acute renal failure (unre-
sponsive to up to 72 h of rehydration, characterized by
creatinine level > 500 µmol/L or urine output < 400 mL/day,
or requiring dialysis); or active or prior hepatitis C infection.
The study is registered with the ISRCTN registry, number
ISRCTN49407852, and clinicaltrialsregister.eu, number
2009-010956-93, and has completed recruitment.
In brief, the trial compared a triplet combination of
cyclophosphamide, lenalidomide, and dexamethasone to a
similar combination with thalidomide (CRD vs. CTD).
Patients were treated for a minimum of four (if transplant
eligible) or six (if transplant non-eligible) cycles and to
maximum response. For patients with a suboptimal response
deﬁned as <VGPR there was a subsequent randomization to a
proteasome inhibitor containing triplet (cyclophosphamide,
bortezomib, and dexamethasone, CVD) or no further therapy.
All patients with stable disease or progression at the end of
initial induction received CVD. Transplant eligible patients
received an autologous stem cell transplant with melphalan
induction. All patients underwent a maintenance randomiza-
tion, which compared lenalidomide maintenance (±vorinostat)
till disease progression vs. observation.
Baseline variables were collected for all patients.
Adverse molecular lesions were determined by qRT-PCR
and MLPA in a central laboratory and were available for
1567/3894 patients. In this approach qRT-PCR is used to
assay the expression of translocation gene partners includ-
ing t(4;14): MMSET, FGFR3; t(14;16): MAF and t(14;20)
MAFB. MLPA was used to assay copy number by including
probesets at sites of the commonly deleted and ampliﬁed
regions in myeloma e.g., at genes CKS1B on 1q21.3 and
TP53 on 17p13. These techniques have been previously
validated and provide equivalent results to interphase
ﬂuorescence in situ hybridization (iFISH) commonly used
in clinical practice [16, 17]. Adverse lesions were deﬁned as
t(4;14), t(14;16), t(14;20), del(17p) and gain(1q) based on
our previous study [7]. Standard risk (SR) was deﬁned as
the absence of any of these lesions, high-risk (HiR) one
lesion and ultra high-risk (UHiR) >1 lesion.
In this analysis we included all patients enrolled into the
Myeloma XI study and summarized important baseline
variables by age in decade groups <60 years (yr), 61–70 yr,
71–80 yr and >80 yr. Variables were compared using
Fisher’s Exact test for categorical characteristics and the
Wilcoxon–Mann–Whitney test for continuous character-
istics with P < 0.05 the level considered statistically sig-
niﬁcant. A multivariate Cox regression analysis was
performed within each age group to identify the variables
with the greatest effect on outcome using complete-case
data. The explained variation in time-to-event endpoints
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was quantiﬁed using R2D [18] and as a proportion of R
2
D for
the chosen “best” model. Relative survival estimates were
obtained using ﬂexible parametric survival models on the
hazard scale with four degrees of freedom [19]. Relative
survival was deﬁned as the observed survival divided by the
expected survival where the expected survival is obtained
from national life tables stratiﬁed by age at diagnosis, sex
and calendar year. United Kingdom life-time risk was
estimated from data available from the Ofﬁce for National
Statistics (https://www.ons.gov.uk/peoplepopulationa
ndcommunity/birthsdeathsandmarriages/lifeexpectancies/da
tasets/nationallifetablesunitedkingdomreferencetables). Sta-
tistical analysis was performed using SAS v9.4 (SAS
Institute Inc., Cary, NC) and Stata IC v13 (StataCorp.
College Station, TX: StataCorp LLC). Some graphs were
drawn using Prism (v7 Graphpad Software Inc.).
Results
The effect of age on primary trial outcomes PFS and
OS
The median age of all patients enrolled in the Myeloma XI
study was 68 years (range 28–92) and their other baseline
characteristics and treatment are shown in Table 1. A sig-
niﬁcant proportion of patients were aged over 80 years (≤60
yr (n= 982), 61–70 yr (n= 1418), 71–80 yr (n= 1247) and
>80 yr (n= 247)). Age was strongly predictive of both
progression-free (PFS) and overall survival (OS) (Fig. 1a,
b). Patients over the age of 80 yr have particularly poor
outcomes with median PFS 13.6 months (95% CI [11.3,
15.4]) and OS 28.9 months (95% CI [23.3, 32.1]) compared
with 38.3 [34.3, 42.8] and 65.6 [64.0, NR] respectively for
patients aged under 60 yr. For each decade increase in age
there was a signiﬁcant stepwise reduction in PFS and OS
with no overlap in 95% conﬁdence intervals between any
adjacent groups (Fig. 1a, b). A comparison of overall sur-
vival using estimates of United Kingdom life-time risk from
data available from the Ofﬁce for National Statistics con-
ﬁrmed an increase in excess deaths with increasing age of
myeloma patients (Fig. 1c and Supplementary Fig. 1)
compared with the general population.
We sought to explain these differences in PFS and OS by
examining patient-related, laboratory and risk variables
across the age groups.
The effect of age on baseline variables
There was an excess of males compared with females across
the trial with no signiﬁcant difference in the proportions
between age groups (Supplementary Fig. 2A) (Female %
≤60 yr 41.3%, 61–70 yr 40.2%, 71–80 yr 43.8% and >80 yr
42.1% p=NS). WHO performance status deteriorated
signiﬁcantly with advancing age (Fig. 2a), the proportion of
patients with performance status 0–1 reduced from 81.9%
for age ≤60 years to 67.0% for those aged >80 years (p <
0.0001). WHO performance status, however, retained
prognostic impact in all age groups (Supplementary Fig. 3).
There was a signiﬁcant increase in the time from when
patients ﬁrst presented with signs/symptoms at the hospital
Table 1 Baseline characteristics of the Myeloma XI population
Characteristic Number of patients (%) total
n= 3894
Sex
Male 2268 (58.2%)
Female 1626 (41.8%)
Age at initial randomization
Mean (SD) 66.6 (10.23)
Median (range) 68 (28, 92)
WHO performance status
0 1338 (34.4%)
1 1540 (39.5%)
2 596 (15.3%)
3 187 (4.8%)
4 21 (0.5%)
Missing 212 (5.4%)
Paraprotein type
IgG 2394 (61.5%)
IgA 953 (24.5%)
IgM 14 (0.4%)
IgD 32 (0.8%)
Light chain only 454 (11.7%)
Non-secretor 24 (0.6%)
Missing 23 (0.6%)
Light chain type
Lamba 1282 (32.9%)
Kappa 2552 (65.5%)
Missing 60 (1.5%)
Randomized induction treatment
CTD 1021 (26.2%)
CRD 1021 (26.2%)
CTDa 924 (23.7%)
CRDa 928 (23.8%)
Maintenance treatment
No maintenance 694 (17.8%)
Lenalidomide ± vorinostat 1164 (29.9%)
Did not undergo maintenance
randomization
2036 (52.3%)
SD standard deviation, CTD cyclophosphamide, thalidomide and
dexamethasone, CRD cyclophosphamide, lenalidomide and dexa-
methasone, CTDa attenuated CTD in the transplant non-eligible
pathway, CRDa attenuated CRD in the transplant non-eligible pathway
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to date of randomization (Supplementary Fig. 2B) with
advancing age.
The proportion of patients with a hemoglobin less than
the predeﬁned cut off for sex altered between age groups
(Supplementary Fig. 2C). There was an age related decline
in renal function (Fig. 2b), as seen in our previous study
MRC Myeloma IX, that was not related to a higher pre-
valence of high serum free light chain levels in the older age
groups [20]. Instead there were fewer cases of light chain
only myeloma in the older cohorts (Supplementary
Fig. 3D). No single paraprotein type increased with age.
Calcium did not change across age groups (Supplementary
Fig. 2E). B2M signiﬁcantly increased with age (Fig. 2c),
which may be a reﬂection of the renal function deteriora-
tion. Albumin decreased with age (Fig. 2c) although this did
not reach statistical signiﬁcance, however in combination
with the B2M increase there was an increase in the pro-
portion of patients with higher International Staging System
(ISS) stages in the older groups (Fig. 2d). ISS retained
prognostic impact in all age groups (Supplementary Fig. 4).
Molecular data was available for 1567 patients. The
proportion of patients with t(4;14) and del(17p) (Fig. 3a)
fell signiﬁcantly with age whilst those with gain(1q)
increased. Overall the proportion of patients with high or
ultra-high risk molecular abnormalities was broadly con-
sistent across the lower three age groups (Fig. 3b). In the
over 80s there was a slightly higher proportion of patients
classiﬁed as high or ultra-high risk.
The relative importance of tumor and patient
variables by age
We have previously demonstrated that molecular risk
lesions predict outcome with groups deﬁned as standard,
high, and ultra high-risk [9]. We conﬁrmed that these
groups remain predictive for both PFS (Fig. 4a) and OS
(Fig. 4b) within each age group but show that the degree of
separation between the risk categories lessened with
advancing age. In the over 80 year group the presence of
only one lesion alone does not associate with adverse out-
come. The presence of del(17p) retained an important effect
on outcome at all ages whilst the adverse effect of t(4;14)
and gain(1q) was reduced in the very elderly (Table 2).
We investigated the relative importance of molecular
events compared with patient related variables by age group
in standard and relative survival models. Multivariate ana-
lysis of both PFS and OS using a Cox regression model was
performed within each age group. The following variables
Fig. 1 Kaplan–Meier survival curves by age group. a Progression free survival b Overall survival
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with the greatest effect on outcome were included in the
“best” model; WHO performance status (PS, 0–4), Inter-
national staging system (ISS, I–III) and molecular risk
(UHiR, HiR, and SR). The percentage of variation
explained by each of these variables was compared between
age groups (Fig. 5). With advancing age molecular risk had
a smaller inﬂuence on outcome, and ISS a greater inﬂuence,
compared with other factors. Performance status had a clear
impact on outcome at all ages suggesting that physical
frailty might be a more important determinant of outcome
than age itself. The patterns were the similar for PFS and
OS.
Discussion
For the ﬁrst time we have demonstrated the relative
importance of myeloma patient and disease-speciﬁc vari-
ables at different ages and their effect on patient outcome.
Whilst factors including ISS and cytogenetic risk remain
prognostic at all ages, we present data showing that their
relative importance alters. We found an increasing inﬂuence
of ISS on outcome with increasing age and a diminishing
inﬂuence of molecular risk status. Performance status
retains prognostic power at all ages suggesting that physical
frailty may be a more important predictor of outcome than
age itself. Although ISS may be considered a disease-
related score, there is likely to be a signiﬁcant impact on ISS
driven by patient factors and a patient’s ability to tolerate
their disease burden. For example high levels of B2M are
associated with renal impairment, and we demonstrate a
reduction in eGFR with age, whilst albumin tends to fall
with increasing age. These patient factors may therefore be
inﬂuencing ISS stage and its impact on outcome.
Importantly we identify a stark difference in outcomes
for myeloma patients of different ages, even with regimens
including novel therapies. When outcomes are normalized
to the UK population we show that patients aged over 80
can expect a median progression-free and overall survival of
only 40% that for patients aged <60.
In our previous study, in the era prior to novel agents,
(published in 2005) we demonstrated a reduction in the
frequency of IgH translocations with age and no prognostic
effect of t(4;14) and del(17p) on outcome for patients over
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Fig. 2 Baseline patient characteristics and laboratory parameters by age
group. a Distribution of WHO performance status by age group. b
Median eGFR by MDRD values indicative of renal impairment by age
group. c Median values of B2M and albumin by age group. d Dis-
tribution of ISS by age group. In all graphs p values indicate an
assessment of difference between the age groups (Fisher’s Exact test for
categorical variables and the Wilcoxon–Mann–Whitney test for con-
tinuous variables). NS= not signiﬁcant. n/a= not available. WHO PS=
World Health Organization Performance Status. eGFR (MDRD)=
estimated glomerular ﬁltration rate by Modiﬁcation of Diet in Renal
Disease Study equation. ISS= International Staging Score
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70 [21]. Findings from that study were limited by small
numbers of patients as well as having limited applicability
to patients treated with current standards of care. More
recently, an analysis of Intergroupe Francophone Myeloma
demonstrated that the t(4;14) and del(17p) retained prog-
nostic signiﬁcance in patients over 65 years but they also
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Fig. 3 Molecular risk parameters
at baseline by age group.
a Adverse translocations and
adverse copy number
abnormalities. b Distribution of
molecular risk group by age
group. SR= standard risk,
HiR= high risk, UHiR=Ultra-
high risk. High-risk molecular
abnormalities were deﬁned as
gain(1q), t(4;14), t(14;16), t
(14;20), and del(17p). Ultra-high
risk was deﬁned as the presence
of more than one high-risk lesion
Fig. 4 Kaplan–Meier survival curves by molecular risk group within
each age group. a Progression free survival b Overall survival. SR=
standard risk (red), HiR= high risk (blue), UHiR=Ultra-high risk
(green). High-risk molecular abnormalities were deﬁned as gain(1q),
t(4;14), t(14;16), t(14;20), and del(17p). Ultra-high risk was deﬁned as
the presence of more than one high-risk lesion
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noted that these lesions had a lower frequency compared
with younger patients [22]. In the Myeloma XI dataset we
have a much larger number of patients and one of the
strengths of the trial is that it had very limited exclusion
criteria making it much more generalizable to ‘real-world’
situations whilst retaining the rigor of a phase III study.
We show that care needs to be taken in risk assignment
using the common myeloma risk scores. The Myeloma
Genome Project Double Hit Classiﬁcation [12] and Mayo
Clinic mSMART criteria [23] rely heavily on tumor factors
rather than patient factors. The Double Hit analysis exclu-
ded patients over the age of 75 because of the signiﬁcant
impact of this factor on outcome. Our ﬁndings suggest these
scores may be very appropriate for younger patients but,
whilst they may retain prognostic signiﬁcance in older
patients, different outcome prediction tools may be better
suited for these groups. We have recently developed a risk
proﬁling approach for transplant-ineligible older patients
[24], and other similar approaches based on assessment of
frailty have also been proposed [25–27].
The R-ISS [8] risk score incorporates cytogenetics
together with the ISS and LDH but does not incorporate
performance status and a criticism of our analysis could be
that we did not include this score in our multivariate ana-
lysis. This was not done mainly because by keeping the ISS
and molecular risk factors separate the contribution of each
to outcome at different ages could be assessed. Further we
only had a limited proportion of patients with LDH data
Table 2 Effect on outcome of individual molecular risk lesions
Age group ≤60 (n= 402) 61–70 (n= 568) 71–80 (n= 507) >80 (n= 90)
HR [95% CI] P value HR [95% CI] P value HR [95% CI] P value HR [95% CI] P value
PFS
t(4;14) 1.79 [1.19, 2.70] 0.0047 1.67 [1.22, 2.27] 0.0012 1.59 [1.05, 2.38] 0.0272 1.35 [0.71, 2.56] 0.3601
del(17p) 1.35 [0.81, 2.22] 0.2442 1.67 [1.19, 2.27] 0.0016 1.61 [0.19, 2.27] 0.0063 3.45 [1.25, 10.0] 0.0107
gain(1q) 1.39 [0.98, 1.96] 0.06 1.39 [1.11,1.72] 0.0035 1.18 [0.95,1.47] 0.1318 1.25 [0.79, 1.96] 0.3399
OS
t(4;14) 1.96 [1.11, 3.45] 0.0189 1.92 [1.25, 2.86] 0.002 1.16 [0.66, 2.04] 0.5903 1.08 [0.48, 2.38] 0.8693
del(17p) 2.86 [1.56, 5.26] 0.0004 2.63 [1.75, 4.00] <0.0001 2.22 [1.43, 3.57] 0.0003 4.00 [1.43, 11.1] 0.0043
gain(1q) 1.85 [1.11, 3.03] 0.0163 1.67 [1.21, 2.27] 0.0016 1.52 [1.14, 2.04] 0.0046 1.05 [0.60, 1.85] 0.8534
Hazard ratio and P value for presence vs. absence of each risk lesion. (P values in bold if <0.05)
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Fig. 5 The percentage of variance explained by molecular risk, ISS,
and WHO PS. a Progression free survival b Overall survival. The
effect of age (PFS: P < 0.0001; OS: P < 0.0001), performance status
(PFS: P= 0.0001; OS: P < 0.0001), ISS (PFS: P < 0.0001; OS: P <
0.0001) and molecular risk (PFS: P < 0.0001; OS: P < 0.0001) on
clinical outcomes is statistically signiﬁcant. SR= standard risk, HiR
= high risk, UHiR=Ultra-high risk. High-risk moelcular abnormal-
ities were deﬁned as gain(1q), t(4;14), t(14;16), t(14;20), and del(17p).
Ultra-high risk was deﬁned as the presence of more than one high-risk
lesion. ISS= International Staging Score. WHO PS=World Health
Organization Performance Status
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available. In addition, a study of the relative contribution of
patient frailty scores to outcome at different ages would
have been beneﬁcial but these were not performed within
the Myeloma XI study. Ultimately scoring systems that
incorporate a wide range of factors, perhaps weighted dif-
ferently based on age, could provide a uniﬁed solution.
We have demonstrated that the spectrum and relative
importance of patient-speciﬁc and tumor acquired biological
and genetic features changes signiﬁcantly across age-groups
of myeloma patients. This is important to understand as we
design disease segmentation strategies to deliver personalized
treatment approaches aiming to improve patient outcomes.
The focus of such approaches in younger patients should be to
target the biology underlying high-risk disease, whilst in older
patients the strategy will require a focus on clinical variables
and treatment type and intensity modiﬁcation.
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